Recently, miR-143 and miR-145 have been shown to belong to a subset of microRNAs whose expression is controlled by a complex of a tumor suppressor p53 and DEAD-box RNA helicase subunits p68/p72. While accumulating studies have acknowledged that both miRNAs function as tumor suppressors and are similarly regulated, evidence of their coordinated action against tumorigenesis has been poorly presented. Herein, we establish transgenic mice that express miR-143 under the control of the CAG regulatory unit. When crossbred with Apc Min/+ mice, the development of tumors in the small intestines is significantly attenuated. In the transgenic small intestine tumors, the endogenous miR-145 is also enhanced and the expression of c-Myc and p68/p72, both of which have been reported to be pivotal for gut tumor development, is suppressed, corresponding to the downregulation of ERK5. We demonstrate that the combination of miR-143 and miR-145 inhibits the expression of c-Myc in human colon cancer cells, whereas miR-145 retards that of p72. Moreover, we show the possibilities that miR-145 modulates p72 expression through its 39 untranslated region and that c-Myc downregulation is involved in both p68 suppression and miR-145 induction. These findings suggest that forced expression of miR-143, probably interacting with endogenous miR-145, inhibits ERK5/c-Myc and p68/p72/b-catenin signaling and hampers small intestine tumor development in Apc Min/+ mice. This unique cascade, in turn, may prevent overproduction of a subset of tumor suppressive miRNAs by repressing their own modulators, p68/p72. 
Introduction
A considerable number of lines of evidence have shown that some sets of microRNA (miRNA) act as oncogenes or as tumor suppressors, and that their biogenesis is closely linked to cancer [1, 2, 3] .
miR-143 and miR-145 have emerged as tumor suppressing miRNAs, particularly for colon cancers. Michael et al. initially reported that the expression of miR-143 and miR-145 was downregulated in many colorectal neoplasms, suggesting their potential action as tumorsuppresors [4] . Indeed, this notion was supported by the following studies, which revealed that the downregulation of miR-143 and miR-145 could be involved in Bcell malignancy [5] and that colon tumor cell proliferation was suppressed by transfection with miR-143 [6] .
However as most of these studies used synthetic miR-143 and miR-145 mimics, their expression was transient and usually far beyond the level normally expressed in living organisms. Hence, their physiological relevance remains to be determined.
Colorectal cancer is one of the most common cancers in not only the Western world but also Japan. Mutations in the Adenomatous polyposis coli (APC) gene are responsible for familial adenomatous polyposis (FAP) syndrome, and are usually an initial event in sporadic cancer development. APC encodes a large multidomain protein that binds to b-catenin and promotes its destruction to downregulate the Wnt signalling pathway [7, 8] .
Apc Min/+ mice, which were established by random mutagenesis with ethylnitrosourea, harbor a heterozygous truncating mutation at codon 850 of Apc and develop tens of small intestinal polyps when on the C57BL/6 background, while quite a few tumors develop in colons [9, 10] .
RNA polymerase II initially transcribes long primary miRNAs (pri-miRNAs) which are generally more than several kilo base pairs (bp) and possess a 59 cap and poly (A) tail. miRNAs mature through a multistep modification with two members of the RNaseIII endonuclease protein family, Drosha and Dicer [11] . Another RNA binding protein, DGCR8, has been found to interact with Drosha and to be a requisite for the processing of primiRNAs. Together with other RNA binding molecules such as DEAD-box RNA helicase subunits p68/p72 (also known as DDX5 and DDX17, respectively), Drosha and DGCR8 form a huge complex, Microprocessor [12] . Indeed, the p68/p72 knockout mice study demonstrated that p68/p72 were required for the processing of pri-miRNAs of a subset of miRNAs, such as miR-145 and miR-16 [13] .
Moreover, Suzuki et al. reported that the processing of pri-miR-143 and pri-miR-145 required the interaction of the tumor suppressor p53 and the Drosha complex through the association with p68/p72 in colon cancer cells, suggesting that the full expression of miR-143 and miR-145 might be involved in tumor suppressing signaling driven by p53 [14] .
On the other hand, accumulating evidence has shown a possible implication of p68/p72 for b-catenin signaling in gut tumor development. The interaction of p68/p72 and b-catenin could play a pivotal role in Wnt/b-catenin signaling, to activate the downstream effectors such as c-Myc, cyclin D1 and c-jun [15] . PDGF-induced tyrosine-phosphorylated p68 associated with bcatenin and promoted the epithelial-mesenchymal transition of human colon cancer cells, suggesting the potential implication of p68 in colon cancer metastasis [16] .
Here, we establish transgenic mice in which miR-143 is ubiquitously expressed in a variety of organs. When crossbred with these mice, the development of small intestine tumors of Apc Min/+ mice is retarded. Interestingly, endogenous miR-145 is also increased in these tumors. Molecular examination shows that protein expression of extracellular signal regulated kinase (ERK5), p68/p72 and c-Myc is strongly suppressed. We also present that the expression of c-Myc and p72 is downregulated by miR-143/ miR-145 and miR-145, respectively, in a human colon cancer cell lines, DLD-1 and Lovo cells. The reporter assay shows that p72 could be a direct target of miR-145.
As far as we are aware, this is the first report that miR-143 suppresses tumors spontaneously developing in living organisms. This study may also provide a unique model where tumor suppressive miRNAs and the key regulators for their biogenesis, p68/p72, form a regulatory circuit.
Results

Forced Expression of miR-143 Induced miR-145 Expression in the Small Intestine Tumors of Apc
Min/+ Mice and Suppressed the Tumor Development
To express miR-143 ubiquitously in whole body, we made a construct which carried ,300 bp human pri-miR-143 fragment under the CAG regulatory unit, composed of CMV enhancer and chicken b-actin promoter, and injected it into the fertilized mice eggs [17] (Fig.1A) . We obtained four founder mice, and three of them transmitted the transgene to offspring. Since only one strain (Line C) strongly expressed miR-143, we used this strain for further analysis (Fig.1B and Fig. S1A ).
The transgenic mice of Line C have no abnormality in appearance. After backcrossing the mice to C57BL/6 mice four times, we crossbred the transgenic mice with Apc Min/+ mice and dissected 4 month old mice to examine the tumor development (Fig. S1B) . Interestingly, the small intestine tumor incidence was significantly suppressed in Apc Min/+ mice carrying the transgene (hereafter referred to as Tg/APC) ( Fig. 2A, 2B, 2C, 2D, 2E ). On the other hand, the colon tumors developed in Tg/APC at higher frequency than non-transgenic littermates (hereafter referred to as W/APC) ( Fig. 2F and 2G ). As far as we examined, all the tumors of Tg/APC were adenomas and histologically showed no apparent difference from those of W/APC (Fig. S2) .
As shown in Fig.3A , miR-143 was highly expressed in the small intestines tumors of Tg/APC whereas the colon tumors generally expressed lower. Thus, the sufficient expression of miR-143 appears to restrain tumor development in living animals.
Unexpectedly, the expression of miR-145 of transgenic small intestine tumors also increased in proportion to that of miR-143 (Fig. 3A) . In contrast, we detected only little enhancement of miR-145 in Tg/APC colon tumors even though one of the tumors examined strongly expressed miR-143 (see Fig.3A #13) . Thus, the induction of endogenous miR-145 appears to work preferentially in the small intestine polyps.
miRNAs are initially transcribed as several kilo bp pri-miRNAs, which are finally cleaved into mature miRNAs through the intermediates, ,65 bp stem-loop precursor miRNAs (pre-miRNAs). miR-143 and miR-145 were transcribed as a bicistronic unit, a common pri-miRNA, in DGCR8-null embryo bodies [18] . To examine whether the upregulation of miR-145 in Tg/APC tumors was due to the increase of pri-miRNA, we performed qRT-PCR analysis of the mouse endogenous pri-miR-143 and primiR-145 with two sets of primers covering each pre-miRNA region. Figure 3B indicated that both of pri-miR-143 and pri-miR-145 expression was upregulated in the small intestine tumors of Tg/APC. Thus, the forced expression of miR-143 in the small intestine tumors may induce the transcription of a bicistronic primiR-143/miR-145 to promote the expression of miR-145, and possibly miR-143. Since no techniques, however, have been available to discriminate the human and the mouse mature miR-143, we could not confirm an auto-regulatory loop of miR-143. On the other hand, neither of pri-miR-143 nor pri-miR-145 significantly increased in the transgenic colon tumors ( Figure 3C ). Hence, the failure of miR-145 induction in transgenic colon tumors seemed to occur at the transcriptional level.
ERK5-c-Myc Signaling was Suppressed in the Transgenic Small Intestine Tumors
Next, we tried to identify the direct target molecule of miR-143 which would contribute the retardation of small intestine tumors. So far, several candidates for miR-143 targets in cancer cells have been identified. Extracellular signal regulated kinase 5 (ERK5) has been the most intensively studied so far. Esau et al. [19] initially documented ERK5 as a target in differentiating adipocytes and other investigators confirmed this notion in some human and rodent cancer cells [5, 20] .
We examined the ERK5 expression in tumors by Western blotting. Corresponding to the miR-143 expression, ERK5 expression in the small intestine tumors of Tg/APC was downregulated compared to W/APC, whereas no significant difference was observed in the colon (Fig. 4A ). Thus, a significant level of miR-143 expression might be necessary for ERK suppression, or colon cells might have low sensitivity of ERK5 to miR-143. Then, we examined the expression of cyclinD1 and cjun that have been shown to be the downstream effectors of ERK5 signaling. As shown in Fig. 4B (1 st and 2 nd panels), both expression was downregulated in the transgenic small intestine tumors.
c-Myc plays a central role in regulation of the proliferation of a variety of cells. Interestingly, the level of c-Myc was closely related to that of ERK5 (Fig. 4B 3 rd and 4 th panels), strongly implicating that c-Myc was one of the major downstream targets of miR-143 through ERK5.
Although c-Myc was proven to be a substrate of ERK5, it was not clear whether the expression of c-Myc was regulated by ERK5 [21] . Since ERK5 is activated by MEK5, we tried to examine the effect of ERK5 activation on c-Myc expression by introducing dominant-negative MEK5A or constitute active MEK5D into human colon cancer cells DLD-1 [22] . As shown in Fig. 5A , the constitutive active MEK5D enhanced the c-Myc expression, whereas the dominant-negative MEK5A rather decreased it. Comparable results were also obtained in human embryonic kidney cells HEK293 (Fig. S3A) Min/+ mice, suggesting the potential consequence of c-Myc stabilization by the MAP kinases in their tumorigenesis [23] .
Next, we examined the effect of miR-143, miR-145 or siRNA for ERK5 on c-Myc expression in DLD-1 cells. Consistent with the results of MEK5 transfection, siRNA for ERK5 clearly repressed c-Myc expression (Fig. 5B, 1 st and 2 nd panels), suggesting that ERK5 could be one of the molecules through which miR-143 regulates c-Myc.
c-Myc expression was not significantly suppressed by either miR-143 or miR-145 mimic when individually transfected. However, when expressed in combination, the effect was much pronounced. (Fig. 5B, 1 st panel). It should be noted that miR-143 mimic significantly downregulated the expression of ERK5 although it was weaker than the effect of siRNA for ERK5 ( p68/p72/b-catenin Signaling was Suppressed in the Transgenic Small Intestine Tumors DEAD-box RNA helicase subunits p68/p72, which are components of Microprocessor, promote the processing of primiR-143 and pri-miR-145 [13, 14] . Thus, we investigated their expression in transgenic tumors. Unexpectedly, both the expression p68 and p78 was drastically inhibited in the small intestine tumors of Tg/APC (Fig.4B 5 th and 6 th panels). This finding was exciting, since a recent study elegantly proved that p68/p72 were critically involved in b-catenin signaling in colon cancers [15] . Interestingly, c-Myc,cyclin D1 and c-jun are also the prominent targets of b -catenin/T-cell factor. miR-145. miR-145 also suppressed the expression of p78 in Lovo cells (Fig.S3B, 2 nd panel). Analysis by TargetScan indicated that there existed one possible binding site of miR-145 in the 39untranslated region (39UTR) of p72 of many animal species. Thus, miR-145 might directly bind the mRNA of p72 and restrain the expression of p72. To test this idea, we constructed a fusion gene of luciferase reporter gene and the p72 39UTR harboring one miR-145 target sequence, and subjected it to reporter assays. A construct with mutations in the seed sequence was made for a negative control (Fig. 5D) . demonstrated that miR-145 mimic decreased reporter activity of vector with the wild 39UTR of p72 by 73% of that of the mutated 39UTR. These results implied that the downregulation of p72 observed in the transgenic small intestine tumors could be at least in part a direct effect of miR-145.
As far as we examined, none of miR-143 and miR-145 mimics significantly inhibited p68 expression in DLD-1 cells and Lovo cells (Fig. 5B, 4 th panel, Fig. S3B , 3 rd panel). Heinlein et al. [25] and Rössler et al. [26] revealed that the 59region of p68 of mouse and human had a canonical E-box, respectively. The latter group furthermore showed that the deletion of the E-box reduced the reporter activity by half. Thus, c-Myc may be one of the candidates that positively regulate p68 expression. To address this hypothesis, we introduced three distinct c-Myc siRNAs into DLD-1 cells and analyzed the expression level of p68. As shown in Fig. 5C , these three siRNAs, all of which strongly suppressed the expression of c-Myc, decreased that of p68. These data implied that failure of suppression of p68 expression by mimics of We also analyzed the signaling in the non-tumorous segments of transgenic small intestines. As shown in Figure S4A , the expression level of miR-145, as well as normal organs (Fig. 1B) , was almost comparable between the transgenic mice and their littermates. Although the expression of ERK5 in non-tumorous segments of Tg/APC small intestines was significantly decreased, retardation of cyclin D1, c-jun and c-Myc expression was subtle or much weaker compared to that in tumors (Fig. S4B, 1 st -4 th panels). The expression of p68 in non-tumorous segments of Tg/APC was inhibited but more slightly than in tumors though its overall expression level seemed to roughly correspond to that of c-Myc (Fig. S4B, 5 th panel), and the suppression of p72 was hardly detected (Fig. S4B, 6 th panel). These data suggested that forced expression of miR-143 should be sufficient for ERK5 repression, but that miR-145 induction might be a crucial event for full inhibition of cyclin D1, c-jun and c-Myc through retardation of 68/p72/b-catenin signaling. Consistent with the ERK5 expression level, c-Myc and p68/p72 were expressed in colon tumors of Tg/APC at similar levels as W/ APC, although the expression of p72 in some samples of Tg/APC was weak (Fig.4C ).
Possible Involvement of c-Myc in the Elevation of miR-145 Expression
To examine whether miR-143 induces the miR-145 expression in human colon tumor cells, we introduced miR-143 mimic into DLD-1 cells and Lovo cells, and analyzed the miR-145 expression by qRT-PCR. There was, however, no obvious enhancement of miR-145 (data not shown). Indeed, although miR-143 was strongly expressed in one colon tumor of transgenic mice, the induction of miR-145 was poor (Fig.3A #13) . Hence, additional events other than miR-143 expression seemed necessary for substantial induction of miR-145 in colon cancer cells. c-Myc is an essential transcription factor in development of tumors and its expression was decreased in the tumors of the intestine but not the colon in Tg/APC. Intriguingly, c-Myc has already been proven to form the feedback loop with miR-17-92 cluster in cancer cells [27] .Thus we introduced siRNA for c-Myc into DLD-1 and Lovo cells. Figure 5F showed that c-Myc siRNA enhanced the expression of miR-145 to some extent in both cells. Moreover, miR143 expression also increased by c-Myc siRNA (Fig. 5G) .
To examine whether the regulation of miR-145 by c-Myc occurred at the transcriptional level, we performed qRT-PCR analysis of pri-miR-145. Consistent with the transgenic intestine tumors, the expression of pri-miR-145 of c-Myc siRNA-introduced cells was increased (Fig 5H) . These data implicated that suppression of c-Myc might be at least partly involved in the elevation of miR-145 and probably of miR-143 in the transgenic intestine tumors.
Discussion
Here, we present that forced expression of miR-143, which is in vivo processed from pri-miRNA, induces miR-145 expression and represses the small intestine tumor formation in Apc Min/+ mice. ERK5, also known as BMK1, is one of the MAP kinases and was shown to be involved in various types of cancers including prostate and breast cancers [28] . While its role in gut cancer development was not clear, the phosphorylation of ERK5 was increased by fetal bovine serum stimulation in Caco-2 cells [29] . Recently, ERK5 was found to be a target of miR-143 in adipocytes [19] .
We demonstrated the expressions of ERK5 and its downstream effectors, c-Myc, c-jun and cyclin D1, were also suppressed in the transgenic small intestine tumors. In particular, c-Myc expression seemed to be tightly linked to the ERK5 expression level.
Of interest, c-Myc has been proven to be a critical mediator of b-catenin signaling in tumorigenesis of intestines after APC loss [23, 30, 31] . The data of our transfection experiments, together with these previous studies, suggest that miR-143 probably inhibits tumor development by downregulating c-Myc expression in cooperation with miR-145 in our transgenic mice.
Downregulation of p68/p72 could also be one of the key factors that retard tumor development in the small intestine of Tg/APC. Our results suggested the downregulation of p72 by miR-145 through binding to its 39UTR might be at least one of the molecular basis for the decrease of its expression in the transgenic small intestine tumors.
In addition, we showed that the expression of p68 was downregulated by the introduction of c-Myc siRNAs. Thus, it is possible that p68 and c-Myc might form a positive feedback loop, which suggests that miR-143 and miR-145 might inhibit p68 in part through the repression of c-Myc.
Further analysis by TargetScan also revealed the existence of possible target sites of miR-206 and miR-34a/miR-206/miR-26a in the 39UTRof p68 and p72, respectively, in a wide range of animal species. This was intriguing, since miR-206 and miR-26a are a set of miRNAs whose processing was proven to depend on the p53/p68/p72 complex [14] . In addition, miR-34a is a wellknown p53-induced gene [32] , and p68 and p72 have been shown to be strong and weak co-activators of p53, respectively [33] . Crucially, all of these were miRNAs that were found to be tumor suppressors [34, 35] .
Indeed, our reporter assays showed that miR-34a ( Fig. S5 B and  F) , miR-206 (Fig. S5 C and G) , and miR-26a (Fig. S5 D and H ) mimics suppressed the reporter activity of the constructs containing each target on the p72 39UTR, whereas miR-206 mimic also decreased that of the construct containing a target on the p68 39UTR ( Fig. S5 A and E) . Although further studies are required, the p53/p68/p72 complex and a set of tumor suppressor miRNAs linked with p53 seem to constitute a novel regulatory feedback circuit.
Whereas miR-145 was induced in the small intestine tumors in Tg/APC, the molecular mechanisms remain to be obscure. Our data using DLD-1 cells and Lovo cells, however, imply that the suppression of c-Myc may be at least in part involved in its induction. Hence, given qRT-PCR analysis of pri-miR-143/145 and Western blot analysis of transgenic tumors, forced-expression of miR-143 might trigger c-Myc/pri-miR-145 signal more easily in the small intestine tumors than in the colon tumors. Interestingly, this signaling axis appeared not to exert its function efficiently in non-tumorous segments of small intestines.
Other investigators recently reported that a positive feedback circuit between miR-143 and miR-145 could work through suppressing KRAS-RREB1 signaling in pancreatic cancer cells, although they did not mention the cross-regulation at the mature miRNA levels [36] . Of note, they showed, however, this circuit was observed only in KRAS mutant cells but not in KRAS wild cells. Since KRAS mutation is not a usual event in tumors of Apc Min/+ mice [9, 10] , the induction of miR-145 by miR-143 in our transgenic mice would be dependent on a molecular mechanism distinct from KRAS-RREB1 signaling. Nonetheless, our study with their report indicates that regulatory circuits between miR-143 and miR-145 might exert anti-tumor effect in a variety of neoplasms in living animals.
The incidence of transgenic colon tumor development, which exhibited poor miR-143 expression, unexpectedly increased compared to non-transgenic littermates. Of interest, this result supports the recent study which compared the tumor incidence in Apc Min/+ mice and APC loxP/+ mice crossed with CDX2P-NLS Cre or Villin-Cre transgenic mice [37] . Their data indicate that the small intestinal tumor burden may inhibit, via an unknown mechanism, the development and/or progression of colorectal tumors in the mouse. In contrast to human cases, APC mutations in mice usually develop far fewer tumors in the colon than the small intestine, for as yet unknown reasons. Further studies will hopefully solve the riddle which underlies gut tumors of the human and the mouse.
In summary, miR-143 and miR-145 likely work together to inhibit at least two signaling pathways involving ERK5/c-Myc and p68/p72/b-catenin in the intestine tumors of Apc Min/+ mice, and thereby suppress their common downstream effectors. Although further studies remain to be investigated, the signaling circuit between miR-143/miR-145 and their modulators p68/p72 might also act as a guardian to arrest the overproduction of the miRNAs (Figure 6 ). The present study may shed new light on the network between cancer-related signaling molecules and miRNAs, which would be more diverged than expected.
Materials and Methods
Mice and Ethics Statement
BCF1 (C57BL/6NRx BALB/c=) females were mated with BCF1 males the night before injection and the eggs were prepared for injection as described previously [38] . Injected eggs were implanted into the oviducts of the pseudo-pregnant ICR mice. Transgenic progeny were backcrossed to C57BL/6J mice. C57BL/6J-Apc Min/+ /J mice were purchased from The Jackson Laboratory. Primers for genotyping are shown in Table S1 .This study was performed in strict accordance with the recommendations in Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan. The protocol was approved by the Committee on the Ethics of Animal Experiments and the Institutional Animal Care and Use of Chubu University (Permit Number: 2210029). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering. Mice Intestinal Tumor Analysis At four months of age, W/APC and Tg/APC mice were euthanized by cervical dislocation to minimize suffering and their small and large intestines were removed and flushed with phosphate buffered saline solution. Intestines were dissected and analyzed for number, location, and size of tumors with the help of a stereoscopic microscope. Some tumors were subjected to RNA and protein analysis and the others were further histologically analyzed by the Hematoxylin-Eosin staining procedure. 
Reagents
DNA Construction
For making the CAG/miR-143, ,300 bp human pri-miR-143 fragment was subcloned into the EcoRI site of pCAGGS vector. To construct CAG/EGFP, the insert fragment of pMXs-puro-EGFP -miR-145/miR-143 [39] was subcloned into XhoI site of pCAGGS vector, and pri-miR-145 fragment was excised by ClaI and NotI. The ends were blunted and self-ligated. A SalI and HindIII fragment of CAG/miR-143 was purified from agarose gels with ELUTIP-D (GE Healthcare UK Ltd.), and injected into eggs. For luciferase reporter assay, the 39UTR fragments of the mouse p68 and p72 containing possible target sites for miR-145, miR-26a, miR-34a or miR-206 were amplified from genomic DNA of a C57BL/6 mouse by PCR using specific primers containing an XhoI site at the 59end. Each fragment was subcloned into XhoI site of the firefly luciferase pGL3-Promoter vector (Promega, Madison, WI, USA), and clones harboring inserts in the forward direction were selected by DNA sequencing. Primers for construction are shown in Table S1 . No new sequence data have not been generated in this study. All experiments were authorized by the Institutional Recombinant DNA Experiment Committee of Chubu University (approval no. 06-8, 08-07).
Cell Culture and DNA/RNA Transfection DLD-1 cells and Lovo cells were grown in RPMI-1640 medium (#189-02025, Wako, Osaka, Japan) and Ham's F-12 medium (#087-08335, Wako) with 10% fetal calf serum, respectively. HEK293 cells were cultured in DMEM medium (#D5796, Sigma) with 10% fetal calf serum. Transfection was performed according to the manufacture's methods. Briefly, DNA plasmids, siRNA or miRNA was mixed with Lipofectamine 2000 (#11668, Invitrogen, Carlsbad, CA, USA) in Opti-MEMI Reduced Serum Medium (#31985, Gibco, Billings, MT, USA), then transfected into 30-40% confluent cells. Seventy two hours after the transfection, cells were subjected to analysis. DLD-1 cells and Lovo cells were purchased from Japan Health Science Research Resources Bank (HSRRB) and grown according to the HSRRB protocol and HEK293 cells were purchased from ATCC.
Western Blot Analysis
Whole cell extracts were prepared by lysing cells in RIPA buffer (10 mM Tris-HCl, pH7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton-X, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate) containing 1 mM phenylmethylsulfonyl fluoride. Fifty,one hundred fifty mg protein was electrophoresed on SDSpolyacrylamide gels, transferred to PVDF membrane (Immobilon, Millipore Corporation, Billerica, MA, USA). The membrane was blocked by 5% skim milk in phosphate buffered saline solution with 0.05% Tween 20 (Sigma) for 30 minutes, stained with each antibody according to the manufactures' methods and thereby subjected to ECL systems. The membrane was analyzed with Image Analyzer LAS-3000 (Fuji Film, Tokyo, Japan).
Northern Blot Analysis
Total RNA was extracted with Trizol (Invitrogen) following the manufacture's manual and separated on 8 M Urea 15% polyacrylamide gels for microRNA analysis, then transferred to Hybond N + (GE Healthcare UK Ltd.). DNA oligonucleotide probes (Table S1) Reverse Transcription and Quantitative Real-time PCR (qRT-PCR) 100 n g of total RNA was subjected to the reverse transcription reaction using TaqMan Reverse Transcription Kit (Life Technologies Co.) and Taqman PCR was performed using Taqman Universal Master Mix II, No AmpErase UNG (Life Technologies Co.) on the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The expression of mature miR-143 and miR-145 was assayed with the Taqman MicroRNA Assays (Applied Biosystems) specific for hsa-miR-143 (P/N: 4395360) and hsa-miR-145 (P/N: 4395389), respectively. snoRNA202 (Life Technologies Co., P/N: 4380914) was used for normalization. For analysis of primary transcript of pri-miRNA, total RNA was extracted by RNAqueous-R-4PCR (Ambion P/N AM1914) and subjected to qRT-PCR using the standard Taqman protocol. b-actin was used for normalization. Evaluation of b-actin expression was performed by the SYBER Green PCR. Briefly, one mg of total RNA was subjected to the reverse transcription reaction using PrimeScript RT reagent Kit (Takara Bio Co., Shiga, Japan). Then, qRT-PCR was done using SYBR premix Ex Taq II (Takara Bio Co.). All values were corrected by each calibration curve and the relative expression level was measured using the DDCt method. Primers for PCR are shown in Table S1 .
Luciferase Reporter Assay 0.5mg of each construct was transfected into 30,40% confluent DLD-1 cells that were cultured in 48-well plates w/wo 10 p mole of miRNA mimics. Seventy two hours after transfection, cells were subjected to Dual-Luciferase Reporter Assay (Promega). For normalization, a renilla luciferase vector, pRL-TK (Promega), was co-transfected.
Statistics
Significant difference from the control was analyzed by the Mann-Whitney U test *: p,0.05, **: p,0.01. Figure S1 Genotyping of mice by PCR. A) PCR analysis of genomic DNA of the transgenic mice DNA extracted from mice tail was analyzed by PCR primers for the vector and human primiR-143(see Fig.1A 
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